<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632448</url>
  </required_header>
  <id_info>
    <org_study_id>ESPS-001</org_study_id>
    <nct_id>NCT02632448</nct_id>
  </id_info>
  <brief_title>A Study of LY2880070 in Participants With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperas Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperas Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this two-part study is to evaluate the safety and efficacy of the study
      drug known as LY2880070 in participants with advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose(s)</measure>
    <time_frame>Baseline through Cycle 1 (Estimated up to 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (Estimated up to 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)</measure>
    <time_frame>Baseline to 24-hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Baseline to 24 hours post-dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax)</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in white blood cell count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in neutrophil count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lymphocyte count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with tumor response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1)</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: LY2880070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY2880070 (Metabolism Phenotype)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2880070</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Part A: LY2880070</arm_group_label>
    <arm_group_label>Part A: LY2880070 (Metabolism Phenotype)</arm_group_label>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>50 to 600 milligrams per square meter of body surface area (mg/m2)</description>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have an estimated life expectancy of greater than or equal to (≥)12 weeks

          -  Have adequate organ function

          -  Have received 1-4 prior systemic therapies for locally advanced or metastatic disease

          -  Agree to use medically approved contraceptives during the study and for 3 months
             following the last study treatment

          -  All females must have a negative serum pregnancy test result, and females of
             child-bearing potential must have a negative urine pregnancy test result, prior to the
             first study treatment

          -  Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1

          -  Must be, in the judgment of the investigator, an appropriate candidate for
             experimental therapy, and no standard therapy would confer clinical benefit

        For Part A

          -  Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain
             tumor) that is advanced or metastatic

          -  For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450
             (CYP2D6) poor metabolizer phenotype

        For Part B

          -  Have advanced or metastatic colorectal cancer, triple negative breast cancer (per
             American Society of Clinical Oncology-College of American Pathology guidelines),
             epithelial ovarian cancer, endometrial, soft tissue sarcoma, pancreatic cancer

               -  For TNBC:

                    -  Recurrent/refractory Triple Negative Breast Cancer (TNBC) defined as any
                       beast cancer that expresses &lt;1% estrogen receptor (ER) and &lt;1% progesterone
                       receptor (PR) and is Her2 negative

               -  For Colorectal (CRC):

                    -  Must have histologically confirmed advanced or metastatic colorectal cancer

               -  For Ovarian Cancer:

                    -  Must have histologically confirmed advanced or metastatic epithelial ovarian
                       cancer

                    -  Must be eligible to receive Gemzar (GEM) and not refractory to
                       GEM/carboplatin

                    -  Must have the ability to tolerate GEM

                    -  May have received GEM as previous therapy

               -  For Endometrial cancer:

                    -  Must have histologically confirmed endometrial cancer that is metastatic or
                       locally advanced

                    -  Must have failed at least 1 prior chemotherapy

               -  For STS:

                    -  Must have histologically confirmed STS that is metastatic or locally
                       advanced

                    -  Patients with gastrointestinal stromal tumors (GIST) must have failed a KIT
                       inhibitor

                    -  Must have failed at least 1 prior chemotherapy

               -  For Pancreatic Cancer:

                    -  Must have histologically confirmed pancreatic cancer that is metastatic or
                       locally advanced

                    -  Must have failed at least 1 prior chemotherapy regimen

        Exclusion Criteria:

          -  Have received treatment with an investigational drug which has not received regulatory
             approval within 21 days of first study treatment

          -  Have symptomatic central nervous system (CNS) metastasis

          -  Females who are pregnant or nursing

          -  Have known positive test results of human immunodeficiency virus, or have chronic
             active hepatitis A, B or C

          -  Have a corrected QT interval (QTcB) greater than (&gt;) 470 milliseconds (msec) (female)
             or &gt;450 msec (male), or a history of congenital long QT syndrome

          -  Have had a bone marrow transplant

          -  Have participated in this study, or are currently enrolled in another clinical study
             of an investigational medicinal product

          -  Have had radiation therapy to &gt;25% of bone marrow

          -  For Part B

               -  Have a history of another active cancer within the past year, except cervical
                  cancer in situ, in situ carcinoma of the bladder, basal cell carcinoma of the
                  skin, or another in situ carcinoma that is considered cured
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: choruspharma@lists.lilly.com</last_name>
    <role>Study Director</role>
    <affiliation>Esperas Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esperas Pharma Inc.</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketki Bhushan</last_name>
      <phone>617-632-4270</phone>
      <email>Ketki_Bhushan@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jas Grewal-Karwa</last_name>
      <phone>313-576-8932</phone>
      <email>karwaj@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Shields</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Chalmers</last_name>
      <phone>(780) 432-8248</phone>
      <email>Bonnie.Chalmers@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Quincy Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Miller</last_name>
      <phone>514-340-8222</phone>
    </contact>
    <investigator>
      <last_name>Wilson Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Provencher</last_name>
      <phone>514-890-8444</phone>
      <email>diane.provencher.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Recurrent cancer</keyword>
  <keyword>Colorectal neoplasms</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Ovarian neoplasms</keyword>
  <keyword>Colon neoplasms</keyword>
  <keyword>Rectal neoplasms</keyword>
  <keyword>Triple negative breast neoplasms</keyword>
  <keyword>Gastrointestinal stromal tumor</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

